Talk
Immunogenicity and Safety of a Live Attenuated Varicella Vaccine in Healthy Children Aged 12 to 15 Months: A Phase III Randomized Controlled Trial
Berlin, Germany
About this session
Registration Nazaire-Bermal Nancy Home Nazaire-Bermal Nancy Immunogenicity and Safety of a Live Attenuated Varicella Vaccine in Healthy Children Aged 12 to 15 Months: A Phase III Randomized Controlled Trial Nazaire-Bermal Nancy Speakers Day 1 University / Institution University of the Philippines Diliman Representing Philippines Abstract The varicella vaccine (VarV) produced by Sinovac (Dalian) obtained World Health Organization (WHO) prequalification in November 2022. However, no direct comparative studies have been conducted between VarV and other WHO-prequalified varicella vaccines.
